GSK to Sell Remaining Stake in Haleon, Looks to Raise $1.52B

GSK on Thursday unveiled plans to let go of its remaining 4.2% stake in its spinoff consumer health brand Haleon, which corresponds to 385 million shares.

The divestment—conducted through Goldman Sachs International and Bank of America—involves offering GSK’s ordinary shares to Haleon’s institutional investors. GSK will determine the offer price through an accelerated bookbuilding offering process, which will start “immediately,” according to its SEC filing.